A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. - Wikidata - awgldk - TriplyDB

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

http://www.wikidata.org/entity/Q36782767

about

Weaponizing human EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) for 21st century cancer therapeutics.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Genomic alterations of ERBB receptors in cancer: clinical implications.Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

P2860

Q37298184-A9DB5A5B-2D1F-456E-B47F-13FA545E3CA4 Q39022941-826CAF28-4588-417D-B407-BE1A2C3BFE69 Q39339970-E45FD889-98A7-4A71-8145-63A943DA69BB Q39383476-B62C2899-8AC7-411E-BE20-7F85FACF728D Q40089704-DB18322B-8A57-45B9-B14E-6568549949E5 Q46008308-4D85D052-A130-4FAD-90A4-9CD52E955CA5 Q47128907-CDD1D30E-E4A2-4474-BD1E-FFD4C047154B Q47318878-C449246A-54E9-437C-A7F4-28B8F3806536 Q49678076-8D779035-A2AD-4553-BD1C-2BB4D6C976F1 Q55262612-EECC384C-8F56-4F40-8DFD-5A81AEFA6857

P2860

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

http://www.wikidata.org/entity/Q36782767

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase II study of bevacizuma ...... GMT unmethylated GBM patients.

@en

type

label

A phase II study of bevacizuma ...... GMT unmethylated GBM patients.

@en

prefLabel

A phase II study of bevacizuma ...... GMT unmethylated GBM patients.

@en

P1433

Q36782767-204EAC9B-BFCC-4D9C-BEA9-EC05B0EE3099

P1476

Q36782767-99629ED8-B16F-4D01-9481-7D04846D3B93

P2093

Q36782767-03EF32D1-47F2-43F6-8E01-314571E76345

Q36782767-1001A946-CC23-4036-9821-44DFD0713BE6

Q36782767-16C51421-78D5-4AC8-B8CC-B72813E53D0D

Q36782767-17D1A8B1-7430-4F8D-8D80-7778FEDDB932

Q36782767-2B43E8B7-E482-4C7B-979D-5957067250D4

Q36782767-2CE5068E-FB16-4132-8686-8738EA5E796E

Q36782767-3158BC06-D7AA-4D1A-9B90-87E9AFD8BE9D

Q36782767-53333064-04BE-440F-AC95-5C98EE5E949B

Q36782767-5FDDB0B3-0961-4DBF-9E57-6B47CF79A06A

Q36782767-6B14771A-1A87-4594-8BBA-AE1F999272EB

P2860

Q36782767-01F4BB93-D4ED-4F6D-928B-A3DB72A805F5

Q36782767-1096D0B2-A0F9-471D-82EF-DB5695948F0A

Q36782767-1DBAFAE7-9F17-4695-8FA4-4A7D4E855E44

Q36782767-2ACB0E2B-52D6-46C7-B1E5-6CCFBFC5466F

Q36782767-301A0FC9-0817-4DC6-9BFB-7D60D14F0A4A

Q36782767-3E8276ED-DD16-4658-AB05-5861160B5211

Q36782767-407A8ABF-82BC-40A2-8022-4A995C0810B4

Q36782767-4A1B7DDE-9B9A-4BFA-9971-8BB44ECA4666

Q36782767-4D4264AB-5366-45E0-A198-7DA27E9F70D5

Q36782767-4DBF8B44-9455-4856-9FD0-18EE8918D0B4

P2888

Q36782767-5F7EBD49-9091-46BB-BFE8-A94DC49C7DFC

P304

Q36782767-E6D9B4D1-9CC6-4F50-A74C-73A7CD581A54

P31

Q36782767-F31F540A-4105-4172-A5B5-44A664A74D04

P356

Q36782767-C9C66AB4-7CE8-4E6A-BE52-0CF73420BE92

P433

Q36782767-940A9E23-E336-436C-B4C0-62B3E6E363B5

P478

Q36782767-A4596A99-E92F-4BAF-BB42-3A7EBBA6C251

P577

Q36782767-F1736933-73AF-434C-B179-82F97B11FAE7

P5875

Q36782767-87B2AE8F-8DBA-49BF-9D39-4ED116768FC0

P698

Q36782767-14CF29E8-1127-4BA9-A35F-9BFACC7D9ACD

P921

Q36782767-1DB10526-2F63-4BC9-B5C6-F8C9E8BB92D8

P932

Q36782767-6225AEB9-1149-4EBF-AB34-97ADED3A9B7F

P356

S11060-015-1958-Z

P1433

Journal of Neuro-Oncology

P1476

A phase II study of bevacizuma ...... GMT unmethylated GBM patients.

@en

P2093

A Rademaker

http://www.w3.org/2001/XMLSchema#string

B Vaillant

http://www.w3.org/2001/XMLSchema#string

Brain Tumor Trials Collaborative

http://www.w3.org/2001/XMLSchema#string

C Conrad

http://www.w3.org/2001/XMLSchema#string

D Liu

http://www.w3.org/2001/XMLSchema#string

I W Tremont-Lukats

http://www.w3.org/2001/XMLSchema#string

J De Groot

http://www.w3.org/2001/XMLSchema#string

J Hu

http://www.w3.org/2001/XMLSchema#string

J J Raizer

http://www.w3.org/2001/XMLSchema#string

J Rudnick

http://www.w3.org/2001/XMLSchema#string

P2860

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

P2888

s11060-015-1958-z

P304

185-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-015-1958-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283013185

http://www.w3.org/2001/XMLSchema#string

P698

26476729

http://www.w3.org/2001/XMLSchema#string

P921

P932

4826294

http://www.w3.org/2001/XMLSchema#string